keyword
https://read.qxmd.com/read/38652539/mirna-148a-containing-gmsc-derived-evs-modulate-treg-th17-balance-via-ikkb-nf-%C3%AE%C2%BAb-pathway-and-treat-a-rheumatoid-arthritis-model
#1
JOURNAL ARTICLE
Jingrong Chen, Xiaoyi Shi, Yanan Deng, Junlong Dang, Yan Liu, Jun Zhao, Liang Rongzhen, Donglan Zeng, Wenbin Wu, Yiding Xiong, Jia Yuan, Ye Chen, Julie Wang, Weidong Lin, Xiangfang Chen, Weishan Huang, Nancy Olsen, Yunfeng Pan, Qing-Ling Fu, Song Guo Zheng
Mesenchymal stem cells (MSCs) have demonstrated potent immunomodulatory properties that have shown promise in the treatment of autoimmune diseases, including rheumatoid arthritis (RA). However, the inherent heterogeneity of MSCs triggered conflicting therapeutic outcomes, raising safety concerns and limiting their clinical application. This study aimed to investigate the potential of extracellular vesicles derived from human gingival mesenchymal stem cells (GMSC-EVs) as a therapeutic strategy for RA. Through in vivo experiments using an experimental RA model, our results demonstrated that GMSC-EVs selectively homed to inflamed joints and recovered Treg and Th17 cells balance, resulting in the reduction of arthritis progression...
April 23, 2024: JCI Insight
https://read.qxmd.com/read/38652484/steroid-tapering-after-gvhd-rx-not-too-fast-not-too-slow
#2
JOURNAL ARTICLE
Paul J Martin
No abstract text is available yet for this article.
April 23, 2024: Blood Advances
https://read.qxmd.com/read/38652480/navigating-the-tumor-microenvironment-mesenchymal-stem-cell-mediated-delivery-of-anticancer-agents
#3
REVIEW
Muhammad Ahsan Waqar, Muhammad Zaman, Muhammad ShafeeqUrRahman, Rabeel Khan, Imtiaz Majeed
Scientific knowledge of cancer has advanced greatly throughout the years, with most recent studies findings includes many hallmarks that capture disease's multifaceted character. One of the novel approach utilized for the delivery of anti-cancer agents includes mesenchymal stem cell mediated drug delivery. Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells that may be extracted from bone marrow, tooth pulp, adipose tissue and placenta/umbilical cord blood dealing with adult stem cells. MSCs are mostly involved in regeneration of tissue, they have also been shown to preferentially migrate to location of several types of tumor in-vivo ...
April 23, 2024: Journal of Drug Targeting
https://read.qxmd.com/read/38652220/ca1-modulates-the-osteogenic-differentiation-of-dental-follicle-stem-cells-by-activating-the-bmp-signaling-pathway-in-vitro
#4
JOURNAL ARTICLE
Jin-Ze Zhao, Ying-Ying Ge, Ling-Fa Xue, Yao-Xiang Xu, Jin Yue, Cong Li, Wen-Lin Xiao
BACKGROUND: Carbonic anhydrase 1 (CA1) has been found to be involved in osteogenesis and osteoclast in various human diseases, but the molecular mechanisms are not completely understood. In this study, we aim to use siRNA and lentivirus to reduce or increase the expression of CA1 in Dental follicle stem cells (DFSCs), in order to further elucidate the role and mechanism of CA1 in osteogenesis, and provide better osteogenic growth factors and stem cell selection for the application of bone tissue engineering in alveolar bone fracture transplantation...
April 23, 2024: Tissue Engineering and Regenerative Medicine
https://read.qxmd.com/read/38652119/long-term-remission-after-upfront-autologous-hematopoietic-stem-cell-transplant-for-cd5-diffuse-large-b-cell-lymphoma
#5
JOURNAL ARTICLE
Yosuke Masamoto, Akira Honda, Aya Shinozaki-Ushiku, Tetsuo Ushiku, Mineo Kurokawa
CD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and nine did not, despite preserved organ function and response after induction therapy...
April 23, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38652075/unveiling-the-uncommon-a-unique-case-of-alps-like-syndrome-complicated-by-plasma-cell-disorder
#6
JOURNAL ARTICLE
Meziane Brizini, Bruno Michon, Marc-Antoine Bédard
Multiple myeloma is a rare disease in pediatrics, where about 30 cases are described under 15 years old. It is even rarer when atypical multiple myeloma occurs in the context of autoimmunity. This case describes a 9-year-old female with autoimmune lymphoproliferative-like disease and combined immune deficiency that developed acute kidney failure with monoclonal peak associated with RAC2 and TNFRSF9 variants. An adapted protocol from the backbone adult multiple myeloma standard of care with the addition of an allogeneic hematopoietic stem cell transplant was used...
April 23, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38652069/variable-clinical-courses-of-varicella-zoster-virus-infection-related-or-vaccination-related-bone-marrow-failure
#7
JOURNAL ARTICLE
Vasil Toskov, Annamaria Cseh, Alexander Claviez, Beatrice Drexler, Natalia Rotari, Stephan Schwarz-Furlan, Matthias Braun, Peter Bader, Peter Lang, Rita Beier, Bernhard Erdlenbruch, Monika Führer, Miriam Erlacher, Charlotte M Niemeyer, Brigitte Strahm, Ayami Yoshimi
We report 5 children with bone marrow failure (BMF) after primary varicella zoster virus (VZV) infection or VZV vaccination, highlighting the highly variable course. Two patients were treated with intravenous immunoglobulins; one had a slow hematologic recovery, and the other was rescued by allogeneic hematopoietic stem cell transplantation (HSCT). Of the 2 patients treated with immunosuppressive therapy with antithymocyte globulin and cyclosporine, one had a complete response, and the other was transplanted for nonresponse...
April 23, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38652054/car-t-therapy-followed-by-hematopoietic-stem-cell-transplantation-can-improve-survival-in-children-relapsed-refractory-philadelphia-chromosome-positive-b-cell-acute-lymphoblastic-leukemia
#8
JOURNAL ARTICLE
Yao Li, Guan-Hua Hu, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Pan Suo, Yu Wang, Yi-Fei Cheng, Xiao-Jun Huang
BACKGROUND: Philadelphia chromosome (Ph)-positive B-cell acute lymphoblastic leukemia (ALL) has a high complete remission (CR) rate, but relapse and prolonged measurable residual disease remain serious problems. We sought to describe the CR rate measurable residual disease negative rate and address the results and safety of pediatric patients who underwent after receiving chimeric antigen receptor (CAR) specific for CD19 (CAR-19) followed by hematopoietic stem cell transplantation (HSCT) for the treatment of Ph-positive ALL...
April 23, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38651865/tandem-autologous-hematopoietic-stem-cell-transplantation-for-patients-with-multiple-myeloma-a-systematic-review-and-meta-analysis
#9
REVIEW
Hongtao Li, Yaxin Zheng, Kehai Gao, Chen Tian
To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction and quality evaluation. Meta-analysis showed that compared to single autologous hematopoietic stem cell transplantation, tandem auto-HSCT does not improve OS, EFS or efficacy in MM patients, and may even lead to higher treatment-related mortality (TRM)...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38651452/post-transplant-cyclophosphamide-versus-anti-thymocyte-globulin-in-patients-with-hematological-malignancies-treated-with-allogeneic-hematopoietic-stem-cell-transplantation-from-haploidentical-and-matched-unrelated-donors-a-real-life-experience
#10
JOURNAL ARTICLE
Bianca Serio, Gabriella Storti, Matteo D'Addona, Lidia Santoro, Camilla Frieri, Danilo De Novellis, Luana Marano, Giovanna De Santis, Roberto Guariglia, Ilenia Manfra, Eleonora Urciuoli, Serena Luponio, Serena Marotta, Denise Morini, Michela Rizzo, Fausto Palmieri, Nicola Cantore, Valentina Giudice, Antonio Maria Risitano, Carmine Selleri
Background: Post-transplant cyclophosphamide (PTCY) is widely used as graft versus host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplant (HSCT) recipients, with reported clinical benefits in patients who underwent transplant from a matched unrelated donor (MUD). However, real-life data on clinical efficacy and safety of PTCY in haploidentical and MUD transplantations are still poor. Methods: In our real-life retrospective observational study, we included a total of 40 consecutive adult patients who underwent haploidentical or MUD HSCT for various hematological malignancies and who received PTCY ( n = 24) or ATG ( n = 16) as GvHD prophylaxis at Hematology Units from hospitals of Salerno and Avellino, Italy, and clinical outcomes were compared...
April 17, 2024: Hematology Reports
https://read.qxmd.com/read/38651451/monitoring-humoral-response-following-bnt162b2-mrna-vaccination-against-sars-cov-2-in-hematopoietic-stem-cell-transplantation-patients-a-single-center-prospective-study-along-with-a-brief-review-of-current-literature
#11
JOURNAL ARTICLE
John V Asimakopoulos, Eleni Lalou, George Seferlis, Maria Malliarou, Eliana Konstantinou, Ioannis Drandakis, Ioannis Vasilopoulos, Angeliki N Georgopoulou, Anastasia Kopsaftopoulou, Alexandros Machairas, Alexia Piperidou, Anestis Karapaschalidis, Maria-Ekaterini Lefaki, Dimitrios Galopoulos, Maria-Panagiota Arapaki, Panagiota Petsa, Ekaterini Benekou, Marina P Siakantaris, Athanasios G Papavassiliou, Panagiotis Tsaftaridis, Panayiotis Panayiotidis, Theodoros P Vassilakopoulos, Angeliki Papapanagiotou, Maria K Angelopoulou
Data on antibody response (AR) after vaccination against SARS-CoV2 in hematopoietic stem-cell transplantation setting (HSCT) were initially scarce, mainly due to the exclusion of such patients from approval studies. Shortly after the worldwide application of vaccination against SARS-CoV-2 in vulnerable populations such as patients with hematologic malignancies, limited single-center trials, including HSCT patients, were published. However, there was a great heterogeneity between them regarding the type of underlying malignancy, co-current treatment, type of vaccine, method of AR measurement, and time point of AR measurement...
April 16, 2024: Hematology Reports
https://read.qxmd.com/read/38651449/ophthalmic-manifestations-in-patients-with-blood-malignancies
#12
REVIEW
Costanza Rossi, Alessandro Buizza, Giuseppe Alessio, Massimiliano Borselli, Andrea Taloni, Adriano Carnevali, Giovanna Carnovale Scalzo, Andrea Lucisano, Vincenzo Scorcia, Giuseppe Giannaccare
Ocular complications can occur in up to 90% of patients with blood malignancies. Such complications range from direct infiltration to local hemostatic imbalance and treatment-related toxicity. This narrative review is based on a systematic computerized search of the literature conducted until January 2024 and examines the common ocular complications associated with blood cancers. Ocular complications from primary disease include mass effects from ocular adnexal lymphomas and intraocular lymphomas, with B-cell lymphomas accounting for 95% of primary ocular presentations...
March 28, 2024: Hematology Reports
https://read.qxmd.com/read/38651248/genomic-testing-identifies-monogenic-causes-in-patients-with-very-early-onset-inflammatory-bowel-disease-a-multi-center-survey-in-an-iranian-cohort
#13
JOURNAL ARTICLE
Golnaz Eslamian, Mahnaz Jamee, Tooba Momen, Pejman Rohani, Sarehossadat Ebrahimi, Mehrnaz Mesdaghi, Soodeh Ghadimi, Mahboubeh Mansouri, Seyed Alireza Mahdaviani, Mahnaz Sadeghi-Shabestari, Morteza Fallahpour, Bibi Shahin Shamsian, Narges Eslami, Samin Sharafian, Naghi Dara, Peiman Nasri, Niloufar Amini, Javad Enayat, Mazdak Fallahi, Leila Ghasemi Hashtrodi, Mohammad Shojaei, Martha Guevara Becerra, Holm H Uhlig, Zahra Chavoshzadeh
Patients with very early-onset inflammatory bowel disease (VEO-IBD) may present because of underlying monogenic inborn errors of immunity (IEI). Strong differences have been observed in the causes of monogenic IBD among ethnic populations. This multi-center study was carried out on 16 Iranian patients with VEO-IBD. We reviewed clinical and basic immunologic evaluation including flow cytometry and immunoglobulin levels. All patients underwent clinical whole exome sequencing (WES). Sixteen patients (8 females and 8 males) with a median age of 43...
April 23, 2024: Clinical and Experimental Immunology
https://read.qxmd.com/read/38650946/innovations-in-bio-engineering-and-cell-based-approaches-to-address-immunological-challenges-in-islet-transplantation
#14
REVIEW
Beatrice Xuan Ho, Adrian Kee Keong Teo, Natasha Hui Jin Ng
Human allogeneic pancreatic islet transplantation is a life-changing treatment for patients with severe Type 1 Diabetes (T1D) who suffer from hypoglycemia unawareness and high risk of severe hypoglycemia. However, intensive immunosuppression is required to prevent immune rejection of the graft, that may in turn lead to undesirable side effects such as toxicity to the islet cells, kidney toxicity, occurrence of opportunistic infections, and malignancies. The shortage of cadaveric human islet donors further limits islet transplantation as a treatment option for widespread adoption...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38650933/eltrombopag-can-promote-platelet-implantation-after-allogeneic-hematopoietic-stem-cell-transplantation-as-safely-and-similarly-to-thrombopoietin
#15
JOURNAL ARTICLE
Yahan Li, Fansheng Kong, Guanchen Bai, Yujie Jiang, Wenlu Zhang, Xue Sun, Xiaohui Sui, Ying Li, Mei Ding, Dai Yuan, Xin Wang, Xiaosheng Fang
BACKGROUND: Eltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT). METHODS: Forty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109 /L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38650799/malignancy-associated-secondary-hemophagocytic-lymphohistiocytosis-mimicking-an-infection-a-case-report-and-review-of-the-literature
#16
Meenakshi Gopalakrishnan, Arunalini Ramanathan, Dhaarani Jayaraman, Sri Gayathri Shanmugam, Julius Xavier Scott
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hematological disorder of immune dysregulation associated with significant challenges in diagnosis and management. Described as primary HLH secondary to genetic defects or more commonly secondary to infections, it can also occur secondary to malignancy, i.e., malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH). A five-year-old male child presented with left cervical adenopathy and a high-spiking fever for two weeks. He had pallor, anasarca, multiple enlarged and matted cervical lymph nodes, respiratory distress, and hepatomegaly...
March 2024: Curēus
https://read.qxmd.com/read/38650581/incidence-and-prevalence-of-musculoskeletal-health-conditions-in-survivors-of-childhood-and-adolescent-cancers-a-report-from-the-swiss-childhood-cancer-survivor-study
#17
JOURNAL ARTICLE
Salome Christen, Katharina Roser, Luzius Mader, Maria Otth, Katrin Scheinemann, Grit Sommer, Claudia Kuehni, Gisela Michel
PURPOSE: Childhood cancer and its treatment can cause damage to the musculoskeletal system. We aimed to determine the incidence and prevalence of musculoskeletal health conditions (MSHC) in survivors, and to investigate differences by cancer-related characteristics. METHODS: We used data from the Childhood Cancer Registry and the Swiss Childhood Cancer Survivor Study, including survivors (≥5 years since diagnosis; diagnosed 1976-2015 at <20 years of age) aged ≥15 years at study...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38650415/-testicular-involvement-in-pediatric-lymphoid-tumors-a-review-of-the-literature-and-a-series-of-clinical-observation
#18
JOURNAL ARTICLE
S Korneeva M, A Batmanova N, R Panferova T, T Valiev T
Lymphoid tumors with testicular involvement in childhood are rare and heterogeneous. The disease may manifest with uni- or bilateral scrotal enlargement. Comprehensive examination includes evaluation of all lymph nodes involvement, as well as ultrasound examination, magnetic resonance imaging and positron emission tomography. A diagnosis is made on basis of morphological and immunohistochemical verification. Determination of lymphoid tumor variant and stage, is recommended to perform chemotherapy according to prognostic risk group, and, in some cases, transplantation of hematopoietic stem cells is required as consolidation therapy...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38650029/mesenchymal-stem-cells-promote-ovarian-reconstruction-in-mice
#19
JOURNAL ARTICLE
Jiazhao Li, Haonan Fan, Wei Liu, Jing Zhang, Yue Xiao, Yue Peng, Weijie Yang, Wenwen Liu, Yuanlin He, Lianju Qin, Xiang Ma, Jing Li
BACKGROUND: Studies have shown that chemotherapy and radiotherapy can cause premature ovarian failure and loss of fertility in female cancer patients. Ovarian cortex cryopreservation is a good choice to preserve female fertility before cancer treatment. Following the remission of the disease, the thawed ovarian tissue can be transplanted back and restore fertility of the patient. However, there is a risk to reintroduce cancer cells in the body and leads to the recurrence of cancer. Given the low success rate of current in vitro culture techniques for obtaining mature oocytes from primordial follicles, an artificial ovary with primordial follicles may be a good way to solve this problem...
April 23, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38650015/stepwise-combined-cell-transplantation-using-mesenchymal-stem-cells-and-induced-pluripotent-stem-cell-derived-motor-neuron-progenitor-cells-in-spinal-cord-injury
#20
JOURNAL ARTICLE
Jang-Woon Kim, Juryun Kim, Hyunkyung Mo, Heeju Han, Yeri Alice Rim, Ji Hyeon Ju
BACKGROUND: Spinal cord injury (SCI) is an intractable neurological disease in which functions cannot be permanently restored due to nerve damage. Stem cell therapy is a promising strategy for neuroregeneration after SCI. However, experimental evidence of its therapeutic effect in SCI is lacking. This study aimed to investigate the efficacy of transplanted cells using stepwise combined cell therapy with human mesenchymal stem cells (hMSC) and induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cells (iMNP) in a rat model of SCI...
April 23, 2024: Stem Cell Research & Therapy
keyword
keyword
6976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.